skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

The cost of biopharmaceutical R&D: is biotech different?

Managerial and decision economics, 2007-06, Vol.28 (4-5), p.469-479 [Peer Reviewed Journal]

Copyright 2007 John Wiley & Sons, Ltd. ;Copyright © 2007 John Wiley & Sons, Ltd. ;Copyright Wiley Periodicals Inc. Jun-Aug 2007 ;ISSN: 0143-6570 ;EISSN: 1099-1468 ;DOI: 10.1002/mde.1360 ;CODEN: MDECDE

Full text available

Citations Cited by
  • Title:
    The cost of biopharmaceutical R&D: is biotech different?
  • Author: DiMasi, Joseph A. ; Grabowski, Henry G.
  • Subjects: Biomedicine ; Biopharmaceutics ; Biotechnology ; Business management ; Capital costs ; Cost analysis ; Cost estimates ; Costs ; Economic costs ; Growth rate ; Medical treatment ; Molecules ; Out of pocket expenses ; Period costs ; Pharmaceutical industry ; Pharmaceutical preparations ; Pharmaceuticals ; R&D ; Research & development ; Research and development ; Studies ; Total costs ; U.S.A
  • Is Part Of: Managerial and decision economics, 2007-06, Vol.28 (4-5), p.469-479
  • Description: The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing the types of molecules on which biotech firms have focused. This study represents a first attempt to get a sense for the magnitude of the R&D costs associated with the discovery and development of new therapeutic biopharmaceuticals (specifically, recombinant proteins and monoclonal antibodies [mAbs]). We utilize drug-specific data on cash outlays, development times, and success in obtaining regulatory marketing approval to estimate the average pre-tax R&D resource cost for biopharmaceuticals up to the point of initial US marketing approval (in year 2005 dollars). We found average out-of-pocket (cash outlay) cost estimates per approved biopharmaceutical of $198 million, $361 million, and $559 million for the preclinical period, the clinical period, and in total, respectively. Including the time costs associated with biopharmaceutical R&D, we found average capitalized cost estimates per approved biopharmaceutical of $615 million, $626 million, and $1241 million for the preclinical period, the clinical period, and in total, respectively. Adjusting previously published estimates of R&D costs for traditional pharmaceutical firms by using past growth rates for pharmaceutical company costs to correspond to the more recent period to which our biopharmaceutical data apply, we found that total out-of-pocket cost per approved biopharmaceutical was somewhat lower than for the pharmaceutical company data ($559 million vs $672 million). However, estimated total capitalized cost per approved new molecule was nearly the same for biopharmaceuticals as for the adjusted pharmaceutical company data ($1241 million versus $1318 million). The results should be viewed with some caution for now given a limited number of biopharmaceutical molecules with data on cash outlays, different therapeutic class distributions for biopharmaceuticals and for pharmaceutical company drugs, and uncertainty about whether recent growth rates in pharmaceutical company costs are different from immediate past growth rates.
  • Publisher: Chichester, UK: John Wiley & Sons, Ltd
  • Language: English
  • Identifier: ISSN: 0143-6570
    EISSN: 1099-1468
    DOI: 10.1002/mde.1360
    CODEN: MDECDE
  • Source: Alma/SFX Local Collection
    RePEc
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait